PBA
APGE icon

Paradigm Biocapital Advisors’s Apogee Therapeutics APGE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209M Buy
1,576,385
+228,142
+17% +$20.6M 3.92% 6
2026
Q1 		$113M Buy
1,348,243
+225,000
+20% +$16.3M 2.32% 15
2025
Q4 		$84.8M Sell
1,123,243
-398,514
-26% -$25.1M 2.16% 15
2025
Q3 		$60.5M Buy
1,521,757
+563,127
+59% +$21.5M 1.72% 18
2025
Q2 		$41.6M Sell
958,630
-3,077
-0.3% -$117K 1.78% 16
2025
Q1 		$35.9M Sell
961,707
-322,059
-25% -$12.5M 1.65% 14
2024
Q4 		$58.2M Buy
1,283,766
+581,949
+83% +$29.7M 2.02% 15
2024
Q3 		$41.2M Buy
701,817
+371,817
+113% +$17.8M 1.39% 23
2024
Q2 		$13M Hold
330,000
– – 0.5% 29
2024
Q1 		$21.9M Buy
+330,000
New +$14.4M 0.77% 27

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Paradigm Biocapital Advisors's APGE Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Apogee Therapeutics (APGE) stake by 17% in Q2 2026, buying an estimated $20.6M and bringing the position to 1,576,385 shares worth $209M. The position accounts for 3.92% of the portfolio, ranked #6.

Paradigm Biocapital Advisors first reported a position in APGE in Q1 2024 and has held it in 10 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Paradigm Biocapital Advisors held 1,576,385 shares of Apogee Therapeutics worth $209M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 228,142 Apogee Therapeutics shares in Q2 2026, an estimated $20.6M.
  • Apogee Therapeutics made up 3.92% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #6 holding.
  • Paradigm Biocapital Advisors first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.